HESH Group and STARR Surgical have reached a "China Strategic Partnership"

• 发布时间:2024-06-06 11:13:57

To promote academic exchanges in the field of ophthalmic optometry and help more myopia patients regain a clear "vision"...

On March 30th, the inaugural He Eye Specialist Hospital (HESH) Group EVO ICL Summit Forum, themed "Brilliant Frontier, Embrace Clarity," was successfully held in Shenyang, Liaoning Province, China. Ophthalmic optometry experts and scholars from across the country gathered together to engage in in-depth discussions on the cutting-edge technology, clinical applications, and future development trends of EVO ICL myopia surgery. Their aim was to jointly promote the rapid and high-quality development of EVO ICL surgery.

During the opening ceremony of the forum, He Eye Specialist Hospital (HESH) Group and STARR Surgical established a "China Strategic Partnership." Shenyang He Eye Specialist Hospital was honored as the "EVO ICL Regional Training Center."

Build a high-level academic platform to promote the development of refractive surgery.

"EVO ICL (Implantable Collamer Lens) surgery" is a widely used refractive surgery in ophthalmology, both domestically and internationally. It can correct myopia and astigmatism, offering advantages such as high definition, non-invasive to the cornea, and reversibility, making it highly favored by a large number of myopia patients.

 Luo Shan, Vice President of Heyi Ophthalmology Group, delivered the opening speech at the forum.

Lu Shan, Vice President of HESH Group, stated that since the introduction of EVO ICL myopia surgery in China in 2006, it has shown rapid development. More and more myopia patients have benefited from it, experiencing a clearer and better quality of life.

HESH Group has always been at the forefront of exploring innovative refractive surgery techniques. At the same time, they are dedicated to training a large number of high-level and high-quality experts in EVO ICL surgery. They continuously upgrade patient care measures during the perioperative period, aiming to provide the highest quality vision correction services to patients.

With the holding of this summit forum as an opportunity, HESH Group will continue to focus on the eye health needs of patients. They will build a high-level academic exchange platform, lead advancements in refractive surgery research and clinical practices, and actively contribute to the high-quality development of eye health in the new era.

He Eye Specialist Hospital (HESH) Group has become the "China Strategic Partner" of STARR Surgical company.

STARR Surgical company is a global leader in the ophthalmic vision correction industry, committed to providing advanced and high-quality vision correction products and solutions for patients and eye care professionals. Their developed EVO ICL technology has brought revolutionary breakthroughs to ophthalmic healthcare. 

With nearly 30 years of establishment, HESH Group has rapidly grown into a group-based chain eye health service organization that integrates medical, education, and research, focusing on comprehensive lifecycle eye health management. In the field of refractive surgery, HESH Group is one of the early ophthalmic medical institutions in China to perform myopia surgery. Today, it has become an important force driving the rapid development of refractive surgery with high quality.

HESH became the "China Strategic Partner" of STARR Surgical Company.

Taking the opportunity of the forum's opening, HESH Group has established a "China Strategic Partnership" with STARR Surgical company.

Liu Juan, the National Channel Sales Director of STARR Surgical company, expressed that HESH Group possesses a team of experienced surgical experts, extensive clinical experience, and meticulous service in the field of EVO ICL. In the future, both parties will focus on common goals, continue to work together, and promote the development of refractive ophthalmology and clinical diagnosis and treatment, enlightening a clear "vision" for more myopia patients.

Shenyang HESH became the "EVO ICL Regional Training Center".

Huang He, the president of Shenyang HESH, and Ren Cuiying, the director of Dalian HESH, won the "EVO ICL Surgery Quality Contribution Award".

In recent years, HESH Group has not only provided clear vision to numerous myopia patients through EVO ICL surgery but has also made outstanding contributions to the overall development of EVO ICL surgery in the region by training and mentoring many surgical doctors. In this forum, He Eye Specialist Hospital was awarded the title of "EVO ICL Regional Training Center." Additionally, Director Huang He of Shenyang HESH and Director Ren Cuiying of Dalian HESH were awarded the "EVO ICL Surgical Quality Contribution Award" for their excellent surgical skills and outstanding contributions to the development of EVO ICL.

Professor Zhou Xingtao from the Eye, Ear, Nose, and Throat Hospital of Fudan University and Professor Shen Ye from the First Affiliated Hospital of Zhejiang University School of Medicine congratulated the first HESH EVO ICL Summit Forum and expressed their anticipation for the wonderful sharing from numerous experts and scholars, working together to drive the thriving development of refractive myopia surgery in China.

Experts and scholars collide with wisdom and share experiences to discuss the future development of EVO ICL.

During the first HESH EVO ICL Summit Forum, numerous experts and scholars in the field of ophthalmic refractive surgery engaged in academic sharing through a combination of online and offline platforms. They delved into various topics such as the latest cutting-edge technologies, EVO ICL lens selection and clinical applications, surgical design, team building, and patient services. The forum provided a platform for in-depth discussions and exchanges on these subjects.

The attending guests engaged in serious discussions and had lively exchanges.

HESH's EVO ICL Myopia Correction Expert Meeting: Opening a Clear Vision World

To ensure that every myopia patient can experience the charm and wonders of ICL surgery, HESH Group has set up a dedicated sub-venue for the expert meeting. Here, patients can have face-to-face interactions with experienced eye care experts, get their doubts clarified, and learn about the most suitable myopia correction surgery options for themselves. Additionally, the sub-venue offers surgical discounts and promotions, allowing patients to enjoy more affordable and high-quality eye care services.

In recent years, EVO ICL surgery has become one of the mainstream procedures for refractive myopia correction, receiving high praise and popularity among patients due to its excellent visual outcomes. The continuous innovation and advancements in EVO ICL technology, as well as the ongoing exploration and progress in clinical applications, are vital forces in ensuring a clear "vision world" for a large number of patients. In the future, HESH Group will continue to strengthen the development of refractive ophthalmology, delve into cutting-edge technologies, drive the rapid growth of EVO ICL in the region, and enable more myopia patients to enjoy a high-definition vision and a better quality of life.